{"id":808715,"date":"2025-02-04T16:04:04","date_gmt":"2025-02-04T21:04:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\/"},"modified":"2025-02-04T16:04:04","modified_gmt":"2025-02-04T21:04:04","slug":"trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\/","title":{"rendered":"TriLink BioTechnologies\u00ae and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap\u00ae mRNA Capping Technology"},"content":{"rendered":"

<\/p>\n

TriLink BioTechnologies\u00ae and <\/b>Aldevron<\/b> Enter into Non-exclusive License and Supply Agreement for CleanCap\u00ae mRNA Capping Technology<\/b><\/p>\n

Enabling the future development of critical therapeutics, <\/i>Aldevron<\/i> customers now have access to TriLink\u2019s CleanCap mRNA capping technology for non-commercial use<\/i><\/p>\n

SAN DIEGO–(BUSINESS WIRE<\/a>)–TriLink BioTechnologies<\/a> (TriLink\u00ae), a Maravai\u00ae LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Aldevron, a leading, global Contract Development and Manufacturing Organization (CDMO) providing high-quality plasmid DNA, RNA, and proteins for research, therapeutics, and diagnostics. With this agreement with Aldevron, TriLink strengthens its objective to provide greater access to CleanCap\u00ae mRNA capping technologies to those developing critical mRNA-based therapeutics and vaccines.<\/p>\n

\nAccording to the terms of the agreement, TriLink will supply its patented CleanCap\u00ae M6, CleanCap\u00ae AG 3\u2019OMe, CleanCap\u00ae AG, and CleanCap\u00ae AU cap analogs for use in Aldevron\u2019s mRNA development and manufacturing services, from pre-clinical through Phase III programs. CleanCap\u00ae technology produces optimal 5\u2019Cap structures with over 95% efficiency, creating a co-transcriptional capping solution that improves mRNA yield and process time when compared to legacy capping methods.<\/p>\n

\n\u201cCleanCap technology is accelerating programs through drug development milestones and has been the capping technology of choice for mRNA constructs in 350+ preclinical and clinical programs,\u201d shared Becky Buzzeo, Chief Commercial Officer, Maravai. \u201cWe\u2019re excited to offer our innovative capping solutions to Aldevron and its manufacturing customers.\u201d<\/p>\n

\nSince its launch in 2017, TriLink\u2019s CleanCap\u00ae capping technology has continued to advance the mRNA capping industry and is used in the majority of all approved COVID-19 mRNA and saRNA vaccines. In May 2023, TriLink introduced its most robust CleanCap\u00ae analog to date, CleanCap\u00ae M6<\/a>, with studies indicating increased mRNA expression by more than 30% versus enzymatic capping methods.<\/p>\n

\nAldevron, based in Fargo, ND, is a leader in advancing biological science. Their custom development and manufacturing services provide scientists with essential components to accelerate research and breakthrough discoveries.<\/p>\n

About TriLink BioTechnologies<\/b><\/p>\n

\nTriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap\u00ae mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders to enabling future pandemic response plans.<\/p>\n

\nFor more information, visit trilinkbiotech.com<\/a>.<\/p>\n

About Maravai LifeSciences<\/b><\/p>\n

\nMaravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines. Maravai\u2019s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world\u2019s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.<\/p>\n

\nFor more information about Maravai LifeSciences, visit maravai.com<\/a>.<\/p>\n

About Aldevron<\/b><\/p>\n

\nAldevron is a premier manufacturing partner, producing high-quality plasmid DNA, RNA, proteins, enzymes, and other key components for the development of vaccines, gene and cell therapies, immunotherapies, and other treatments. Headquartered in Fargo, North Dakota, and as a part of the Danaher Corporation (NYSE: DHR) family of global science and technology companies, Aldevron supports thousands of scientists who are developing revolutionary, lifesaving treatments for millions of people. To learn more about how Aldevron is advancing biological science, visit www.aldevron.com<\/a>.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250204333920\/en\/<\/a><\/span><\/p>\n

\nMedia contact:
\n
Liz Robinson of CG Life
\n
TriLink BioTechnologies
\n
+1 312-997-2436
\n
lrobinson@cglife.com<\/a><\/p>\n

\nEllen Shafer
\n
Senior Director of Communications
\n
Aldevron
\n
O: 701-551-8704
\n
ellen.shafer@aldevron.com<\/a><\/p>\n

\nInvestor contact:
\n
Deb Hart
\n
Maravai LifeSciences
\n
+ 1 858-988-5917
\n
ir@maravai.com<\/a><\/p>\n

KEYWORDS:<\/b> California Europe United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Science Other Science Biotechnology Research Health FDA Infectious Diseases Other Health<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

TriLink BioTechnologies\u00ae and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap\u00ae mRNA Capping Technology Enabling the future development of critical therapeutics, Aldevron customers now have access to TriLink\u2019s CleanCap mRNA capping technology for non-commercial use SAN DIEGO–(BUSINESS WIRE)–TriLink BioTechnologies (TriLink\u00ae), a Maravai\u00ae LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Aldevron, a leading, global Contract Development and Manufacturing Organization (CDMO) providing high-quality plasmid DNA, RNA, and proteins for research, therapeutics, and diagnostics. With this agreement with Aldevron, TriLink strengthens its objective to provide greater access to CleanCap\u00ae mRNA capping technologies to those developing critical mRNA-based therapeutics and vaccines. According to the terms of the … <\/p>\n

Continue reading “TriLink BioTechnologies\u00ae and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap\u00ae mRNA Capping Technology”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-808715","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTriLink BioTechnologies\u00ae and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap\u00ae mRNA Capping Technology - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TriLink BioTechnologies\u00ae and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap\u00ae mRNA Capping Technology - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TriLink BioTechnologies\u00ae and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap\u00ae mRNA Capping Technology Enabling the future development of critical therapeutics, Aldevron customers now have access to TriLink\u2019s CleanCap mRNA capping technology for non-commercial use SAN DIEGO–(BUSINESS WIRE)–TriLink BioTechnologies (TriLink\u00ae), a Maravai\u00ae LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Aldevron, a leading, global Contract Development and Manufacturing Organization (CDMO) providing high-quality plasmid DNA, RNA, and proteins for research, therapeutics, and diagnostics. With this agreement with Aldevron, TriLink strengthens its objective to provide greater access to CleanCap\u00ae mRNA capping technologies to those developing critical mRNA-based therapeutics and vaccines. According to the terms of the … Continue reading "TriLink BioTechnologies\u00ae and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap\u00ae mRNA Capping Technology"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-04T21:04:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250204333920r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"TriLink BioTechnologies\u00ae and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap\u00ae mRNA Capping Technology\",\"datePublished\":\"2025-02-04T21:04:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\\\/\"},\"wordCount\":648,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250204333920r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\\\/\",\"name\":\"TriLink BioTechnologies\u00ae and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap\u00ae mRNA Capping Technology - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250204333920r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-02-04T21:04:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250204333920r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250204333920r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TriLink BioTechnologies\u00ae and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap\u00ae mRNA Capping Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TriLink BioTechnologies\u00ae and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap\u00ae mRNA Capping Technology - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\/","og_locale":"en_US","og_type":"article","og_title":"TriLink BioTechnologies\u00ae and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap\u00ae mRNA Capping Technology - Market Newsdesk","og_description":"TriLink BioTechnologies\u00ae and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap\u00ae mRNA Capping Technology Enabling the future development of critical therapeutics, Aldevron customers now have access to TriLink\u2019s CleanCap mRNA capping technology for non-commercial use SAN DIEGO–(BUSINESS WIRE)–TriLink BioTechnologies (TriLink\u00ae), a Maravai\u00ae LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Aldevron, a leading, global Contract Development and Manufacturing Organization (CDMO) providing high-quality plasmid DNA, RNA, and proteins for research, therapeutics, and diagnostics. With this agreement with Aldevron, TriLink strengthens its objective to provide greater access to CleanCap\u00ae mRNA capping technologies to those developing critical mRNA-based therapeutics and vaccines. According to the terms of the … Continue reading \"TriLink BioTechnologies\u00ae and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap\u00ae mRNA Capping Technology\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-04T21:04:04+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250204333920r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"TriLink BioTechnologies\u00ae and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap\u00ae mRNA Capping Technology","datePublished":"2025-02-04T21:04:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\/"},"wordCount":648,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250204333920r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\/","name":"TriLink BioTechnologies\u00ae and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap\u00ae mRNA Capping Technology - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250204333920r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-02-04T21:04:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250204333920r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250204333920r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trilink-biotechnologies-and-aldevron-enter-into-non-exclusive-license-and-supply-agreement-for-cleancap-mrna-capping-technology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"TriLink BioTechnologies\u00ae and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap\u00ae mRNA Capping Technology"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/808715","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=808715"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/808715\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=808715"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=808715"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=808715"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}